Close menu




Covid19

Photo credits: pixabay.com

Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

  • Biotechnology
  • Cancer
  • Covid19
  • Investments

Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

Read

Commented by Stefan Feulner on January 12th, 2023 | 14:33 CET

Powerful movements in the biotech sector - CureVac, Cardiol Therapeutics, Ambrx Biopharma

  • Biotechnology
  • Covid19
  • Cancer

That the biotech sector stands for high volatility is nothing new. Price jumps of more than 50% in one day after study results are no exception. Last year, the capital-intensive sector of the future suffered from the change in strategy by the central banks with several interest rate hikes. The Nasdaq Biotech Index alone lost around 50% of its value in some cases. In addition, smaller stocks that do not yet have a commercial product on the market experienced massive upheavals. The speed with which a rebound can set in was demonstrated not only by vaccine producer CureVac.

Read

Commented by Armin Schulz on January 9th, 2023 | 17:35 CET

BioNTech, Defence Therapeutics, Bayer - Is a Corona tsunami imminent?

  • Biotechnology
  • Covid19
  • Cancer

At the beginning of December, things were quiet concerning Corona. The feared wave failed to materialize, and there were no new variants. On December 7, China announced a relaxation of Corona measures. Now the country is facing a gigantic Corona wave. Many European countries have already imposed mandatory testing for entry from China. Germany has now followed suit. In parallel, the Consumer Electronics Show 2023 ran from the 5th to the 8th in Las Vegas, where all kinds of companies from all over the world presented their latest technology. Chinese companies also exhibited there. Because of the multitude of infections, new deadly mutations could emerge. As a result, pharmaceutical and biotech companies are coming back into focus.

Read

Commented by André Will-Laudien on January 5th, 2023 | 06:35 CET

It is the year 2023 and COVID is back! BioNTech, Bayer, Defence Therapeutics, Morphosys - Which stocks stand up to the virus from China?

  • Biotechnology
  • Covid19
  • Cancer

The next COVID wave is raging in China. The situation is no less dramatic today than in 2019 because until now, only vaccines produced in the country may be administered to locals in China. Before Christmas, however, the German government obtained permission to have Germans in China vaccinated with the active ingredient from BioNTech and immediately had the first doses flown out to Beijing. Yesterday, the EU discussed a joint reaction to the current conditions in China. German medical officials are calling for mandatory Europe-wide testing of all people entering the country and are warning of a new, dangerous virus mutation due to the large numbers of infections. Investors are therefore taking the vaccine experts back into focus.

Read

Commented by Stefan Feulner on January 3rd, 2023 | 08:30 CET

Growing optimism at Deutsche Bank, Alerio Gold and Sartorius

  • Mining
  • Gold
  • Investments
  • Covid19

The volatile and weak stock market year 2022 is history, but the issues with rising inflation combined with fears of recession as well as the uncertainties in geopolitics with existing and threatening conflicts in Ukraine and Taiwan remain. Thus, at least the high volatility is likely to continue. Despite all the imponderables, many experts see opportunities for a thoroughly positive stock market year. In the gold sector, too, new price targets beyond 2000 are already being passed around. Many shares from this sector therefore offer attractive long-term entry opportunities at a reduced level.

Read

Commented by André Will-Laudien on January 3rd, 2023 | 07:26 CET

New COVID outbreak in China: BioNTech, Cardiol Therapeutics, CureVac and Valneva shares in focus again in 2023

  • Biotechnology
  • Covid19
  • heartdisease

The next COVID wave is rolling towards Europe. Representatives of the EU states therefore want to discuss a unified approach on Wednesday due to the latest development in China. The main issue is how to deal with entrants from China. A spokeswoman for the Federal Ministry of Health in Berlin said that the situation is being closely monitored and that the EU partners are also being consulted. At French airports, arrivals from China are already generally tested for the virus. Italy and Spain have also reacted with corresponding regulations. The German government sees no reason to do so so far. Is Germany too slow again, or is prudence the order of the day?

Read

Commented by Stefan Feulner on December 30th, 2022 | 17:52 CET

BioNTech, Defence Therapeutics, Pfizer - The cards are being reshuffled

  • Biotechnology
  • Covid19
  • Investments

The Corona pandemic is seemingly coming to an end after almost three long years. The return to normality, now in China and the rest of the world, is a relief for society and the economy. In contrast, vaccine manufacturers are losing a billion-dollar business that is difficult to compensate for with products in other areas of application. Nevertheless, the stock market valuations of the vaccine producers continue to be exorbitantly high, as does their drop in value.

Read

Commented by Nico Popp on December 8th, 2022 | 09:05 CET

Where the money is made: BioNTech, Novavax, Cardiol Therapeutics

  • Biotechnology
  • Covid19
  • CBD

While the first federal states in Germany are lifting the mask requirement on public transport, suppliers of vaccines and medicines are far from going back to normal. Even corona vaccines are in high demand. While there is a shortage of antipyretics and medication in this country, especially for children, innovative companies are already addressing the next challenges. We explain where investors can make money.

Read

Commented by Nico Popp on November 30th, 2022 | 13:33 CET

Advances in the fight against cancer: Arcus Biosciences, Gilead Sciences, Defence Therapeutics, BioNTech

  • Biotechnology
  • Covid19
  • Cancer

Research studies from 2020 show that 72% of Germans fear cancer. However, very few people want to admit to these fears. But precisely because the subject is a big taboo, it is worth looking at the latest achievements in research. Many companies worldwide have long been fighting the epidemic - and making astonishing progress. Just recently, a US biotech announced encouraging study results. Other companies have yet to launch promising studies. We provide an overview and outline opportunities from an investor's perspective.

Read

Commented by Stefan Feulner on November 25th, 2022 | 23:16 CET

Viromed Medical AG, Encavis AG, K+S - The foundation is laid

  • Covid19
  • Investments

For weeks now, the most important stock markets around the globe have been on an upward trend. What was initially only declared as a countermovement in the overriding downward movement could now be the start of a more pronounced year-end rally. While indices such as the DAX and the Dow Jones have already managed to break out of the downtrends they have been following since the start of the Ukraine war, smaller stocks, in particular, still offer considerable catch-up potential.

Read